Hassane Mohamed Zarour MD
Professor, Medicine and Dermatology, University of Pittsburgh School of Medicine
Join to view full profile
5117 Centre AveResearch Pavilion, Suite 1.32aPittsburgh, PA 15213
Phone+1 412-623-3272
Dr. Zarour is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Hassane Zarour is a dermatologist based in Pittsburgh, PA, with a focus on skin cancers, melanoma, and cancer immunotherapy. He completed his dermatology and cutaneous oncology education at the University of the Marseille Faculty of Medicine in 1991. Dr. Zarour has authored several notable publications on melanoma and immunotherapy, including those on the impact of gut microbiota on antitumor immunity in metastatic melanoma. His work has been cited by other publications numerous times. Additionally, he has been involved in clinical trials exploring advanced melanoma treatments with various investigational therapies. His clinical practice focuses on skin cancer and melanoma, diagnosis and treatment as well as diagnosis and treatment of cutaneous adverse events upon immunotherapy of cancer.
Education & Training
University of the Mediterranean Faculty of MedicineClass of 1991, Dermatology and Cutaneous Oncology
Certifications & Licensure
PA State Medical License 2003 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2015-2016
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2015-2016
Clinical Trials
- CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors
- NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2014 Jan 24
- Treatment of Advanced Melanoma With MK-3475 and Peginterferon Start of enrollment: 2014 Jul 24
Publications & Presentations
PubMed
- Toward a Dual-Axis Model of Microbiome Modulation in Cancer Immunotherapy: Pathobiont Elimination and Functional Ecosystem Restoration.Diwakar Davar, Hassane M Zarour, Giorgio Trinchieri
Cellular and Molecular Bioengineering. 2026-07-08 - 1 citationsImproving immunotherapy in solid tumors using FMT.Diwakar Davar, Hassane M Zarour, Giorgio Trinchieri
Cell. 2026-04-16 - 7 citationsHarnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Hassane M Zarour, Giorgio Trinchieri
Annual Review of Immunology. 2026-04-01
Press Mentions
Combination Therapy Shows Promising Results in Treating Stage 3 MelanomaOctober 31st, 2024- Fecal Microbiota Transplants May Improve Resistance to Melanoma ImmunotherapyOctober 13th, 2021
- Fecal Microbiota Transplant Changes Melanoma Immunotherapy Non-Responders to RespondersFebruary 5th, 2021
Grant Support
- Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumorsUNIVERSITY OF PITTSBURGH AT PITTSBURGH2022–2027
- Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in MelanomaUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2026
- Melanoma and Skin Cancer Program SPOREUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2026
- Reversing Melanoma-Induced T Cell DysfunctionNational Cancer Institute2011–2012
- Optimization Of Melanoma Vaccines With T-Helper EpitopesNational Cancer Institute2009–2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: